High potency ADCs - from discovery to the clinic
KTN will be holding this event, in partnership with MedImmune, on Monday 11th December 2017 in Cambridge. The aim of the meeting is to bring together the Antibody Drug Conjugate discovery, development and manufacturing community in human health in the UK.
Come and join us to:
- Learn about the latest innovative technologies in target identification, process development and manufacturing of all component parts of ADCs
- Catch up on novel toxins and linkers being developed
- Share in the success of ADCs already in clinical development
- Hear about UK capabilities and future opportunities for this sector, identified in the MMIP Technology and Innovation workstream of funding opportunities to support innovative companies through Innovate UK, and mechanisms such as the Industrial Strategy Challenge Fund.
We are expecting about 90 delegates on the day from the wider sector. Thanks to the generosity of our hosts, and supporters including Glythera and ADC Biotechnology, KTN is able to deliver this meeting as a free event for the community.